Last reviewed · How we verify
L- DOPA
At a glance
| Generic name | L- DOPA |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Drug class | Aromatic Amino Acid [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PET Scanning in Parkinson s Disease
- Diagnosis of Pheochromocytoma (PHASE1)
- Cortical Electrophysiology of Response Inhibition in Parkinson's Disease (PHASE4)
- Dopamine Modulation of Motivation and Motor Function in Major Depression & Inflammation (NA)
- An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L- DOPA CI brief — competitive landscape report
- L- DOPA updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI